8-K filing — ACTUATE THERAPEUTICS, INC. (ACTU)
Filed: 2026-10-28 AccNo: 0001683168-26-008143 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Top Wall Street analysts changed their outlook on various stocks. Check out the analyst ratings page for upgrades, downgrades, and initiations.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-28 AccNo: 0001683168-26-008143 Size: 1 MB Item 1.01: Entry into a Material Definitive Agreement Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Actuate Therapeutics, Inc. has priced an underwritten public offering of its securities to raise $11.0 million in gross proceeds.
XCF Global surged 64.9% premarket after completing a business combination and forecasting 2025 revenue of $120M-$130M and EBITDA of $70M-$75M.
Koses has extended its contract to supply automated electrode cell equipment to Bloom Energy through October 2027.
Global electricity demand is projected to grow 3.8% next year, driven by AI data centers, manufacturing reshoring, and EV adoption. Solar will lead growth with 600 TWh annually through 2027, while nuclear capacity will expand through plant restarts and uprates. Natural gas serves as a bridge fuel with 48 GW needed by 2035 to meet data center demand. Data center energy consumption could reach 945 TWh by 2030 and 1,200 TWh by 2035.